Articles

Sherley v. Sebelius: Where do we go from here?

“What we have going on right now with hESC research is the civil rights movement of the 21st century, a debate on whether science is going to enslave and manipulate the embryo,” says Samuel Casey, managing director and general counsel for the Law of Life Project, the law firm that represented the plaintiffs in Sherley v. Sebelius. “They are the new slaves. They are too small to vote. We are reopening the door on human subject experimentation, something that until now, only World War II closed the door on. I have spent the last 10 years trying to point out the truth, and this is where we today.”
Written byAmy Swinderman
| 4 min read

In the 1960s, McCulloch-Till discovered stem cells while studyingthe effect of radiation on the bone marrow of mice. In the 1980s, two groups ofresearchers derived embryonic stem cells from mouse embryos. In the 1990s,James Thomson developed a technique to isolate and grow human embryonic stemcells (hESCs) in a cell culture. In 2006, Shinya Yamanaka successfullytransformed human fibroblasts into pluripotent stem cells using four genes witha retroviral system.

With each groundbreaking discovery, thousands of people—fromthe world's top scientists to average Joes—began to question some of theethical, moral and social aspects of stem cell research, and in 1995, Americanlawmakers attempted to address those concerns in the form of Dickey-Wicker, anappropriations bill rider that prohibited the National Institutes of Health(NIH) from using government funds for the creation of human embryos forresearch purposes, or for research in which human embryos are destroyed. In theearly 2000s, President George W. Bush issued an executive order restricting theuse of federal funds for hESC research. A few years later, his successor,President Barack Obama, reversed that order.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Digital illustration of a human brain composed of glowing neural connections, surrounded by colorful, blurred lights against a dark blue background.
Discover how researchers are looking beyond individual neurons to understand how genetic variations shape activity across brain organoid networks.
3D illustration of a Y-shaped antibody with pink and blue molecular structures against a blurred pink and purple background.
Explore how dual binding assays reveal interactions between bispecific antibodies and their targets, providing insights into binding behavior and antibody function.
3D molecular illustration of protein structures in blue, yellow, and purple, with small molecules bound to their surfaces against a dark background.
Advances in biolayer interferometry enable the analysis of small molecule interactions, providing new insights into binding kinetics and affinity.